You are here

ENDOPROTECH, INC.

Company Information
Address
1044 E CHESTNUT ST
LOUISVILLE, KY 40204-1019
United States



Information

UEI: TGWXNHCYTTR3

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction

    Amount: $1,485,754.00

    According to the CDC inischemic heart disease is the leading cause of death worldwideand in the US approximatelypatients died of ischemic heart diseaseIt is well established in clinical practice that ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  2. A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction

    Amount: $224,812.00

    DESCRIPTION provided by applicant According to the CDC in ischemic heart disease is the leading cause of death worldwide and in the US approximately patients died of ischemic heart d ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  3. Novel Drug Carrier System for the Treatment of Alcoholic Liver Disease

    Amount: $1,414,341.00

    DESCRIPTION provided by applicant Alcoholic Liver Disease ALD remains a leading cause of death from liver disease in the U S and no FDA approved therapy exists Abnormal cytokine metabolism is ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
  4. Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

    Amount: $277,707.00

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabo ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  5. New anti-complement therapy to reduce reperfusion injury: Phase II

    Amount: $963,666.00

    DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to d ...

    STTRPhase II2008Department of Health and Human Services National Institutes of Health
  6. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    STTRPhase I2005Department of Health and Human Services National Institutes of Health
  7. New anti-complement therapy to reduce reperfusion injury

    Amount: $122,978.00

    DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia rep ...

    SBIRPhase I2005Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government